Sirolimus drug-eluting stent already registered in
It was learnt in the 13th Great Wall Cardiology Society held recently that the sirolimus drug-eluting stent developed and produced by Johnson & Johnson will be put into wide clinical application in China shortly; the stent will effectively prevent postoperative restenosis of intra-coronary artery stent.
Professor Gao Runlin of Beijing Fuwai Hospital said that the clinical trial on sirolimus drug-eluting stent started last year in Beijing Fuwai Hospital and People's Hospital of Guangdong province. Up to the present, 41 cases had undergone the procedure; 20 cases were followed-up for 6 months and there is as yet no restenosis occurred, nor is there any side effect or complication. The remaining 21 cases are still under follow-up. The sirolimus drug-eluting stent was already in widespread application in approximately 20 countries in Europe and Asian-Pacific regions and around 10 thousand patients were registered to accept the treatment in the world., 百拇医药
Professor Gao Runlin of Beijing Fuwai Hospital said that the clinical trial on sirolimus drug-eluting stent started last year in Beijing Fuwai Hospital and People's Hospital of Guangdong province. Up to the present, 41 cases had undergone the procedure; 20 cases were followed-up for 6 months and there is as yet no restenosis occurred, nor is there any side effect or complication. The remaining 21 cases are still under follow-up. The sirolimus drug-eluting stent was already in widespread application in approximately 20 countries in Europe and Asian-Pacific regions and around 10 thousand patients were registered to accept the treatment in the world., 百拇医药